Mutant SOD1-induced neuronal toxicity is mediated by increased mitochondrial superoxide levels.
Amyotrophic lateral sclerosis (ALS), the most common motor neuron disease in adults, is characterized by the selective degeneration and death of motor neurons leading to progressive paralysis and eventually death. Approximately 20% of familial ALS cases are associated with mutations in SOD1, the gene encoding Cu/Zn-superoxide dismutase (CuZnSOD). Previously, we reported that overexpression of the mitochondrial antioxidant manganese superoxide dismutase (MnSOD or SOD2) attenuates cytotoxicity induced by expression of the G37R-SOD1 mutant in a human neuroblastoma cell culture model of ALS. In the present study, we extended these earlier findings using several different SOD1 mutants (G93C, G85R, and I113T). Additionally, we tested the hypothesis that mutant SOD1 increases mitochondrial-produced superoxide (O(2) (*)) levels and that SOD2 overexpression protects neurons from mutant SOD1-induced toxicity by reducing O(2) (*) levels in mitochondria. In the present study, we demonstrate that SOD2 overexpression markedly attenuates the neuronal toxicity induced by adenovirus-mediated expression of all four SOD1 mutants (G37R, G93C, G85R, or I113T) tested. Utilizing the mitochondrial-targeted O(2) (*)-sensitive fluorogenic probe MitoSOX Red, we observed a significant increase in mitochondrial O(2) (*) levels in neural cells expressing mutant SOD1. These elevated O(2) (*) levels in mitochondria were significantly diminished by the overexpression of SOD2. These data suggest that mitochondrial-produced O(2) (*) radicals play a critical role in mutant SOD1-mediated neuronal toxicity and implicate mitochondrial-produced free radicals as potential therapeutic targets in ALS.
Zimmerman
Matthew C
MC
Free Radical and Radiation Biology Program, Department of Radiation Oncology, The University of Iowa, Iowa City, Iowa 52242, USA.
Oberley
Larry W
LW
Flanagan
Shawn W
SW
D000690:Amyotrophic Lateral Sclerosis / Q000235:genetics / Q000378:metabolism*; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use; D016923:Cell Death; D045744:Cell Line, Tumor; D002490:Central Nervous System / Q000378:metabolism; D019610:Cytoprotection / Q000235:genetics; D005822:Genetic Vectors; D006801:Humans; D007202:Indicators and Reagents; D008928:Mitochondria / Q000378:metabolism*; D009154:Mutation / Q000235:genetics; D009410:Nerve Degeneration / Q000235:genetics / Q000378:metabolism; D009474:Neurons / Q000378:metabolism*; D018384:Oxidative Stress / Q000235:genetics* / Q000502:physiology; D010617:Phenanthridines; D013482:Superoxide Dismutase / Q000235:genetics / Q000378:metabolism / Q000633:toxicity*; D000072105:Superoxide Dismutase-1; D013481:Superoxides / Q000378:metabolism*; D014162:Transfection; D015854:Up-Regulation / Q000235:genetics; D000099156:Superoxide Dismutase 2
D000975:Antioxidants; D007202:Indicators and Reagents; D010617:Phenanthridines; D013482:Superoxide Dismutase; D000072105:Superoxide Dismutase-1; D013481:Superoxides; D000099156:Superoxide Dismutase 2; C521281:5-(6'-triphenylphosphoniumhexyl)-5,6-dihydro-6-phenyl-3,8-phenanthridinediammine; C000606290:SOD1 protein, human